Trade this ETF at your broker
Fund size | EUR 435 m |
Total expense ratio | 0.35% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 17.32% |
Inception/ Listing Date | 19 October 2017 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | Deloitte |
Fiscal Year End | 31 May |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Vertex Pharmaceuticals, Inc. | 9.02% |
Amgen, Inc. | 8.61% |
Regeneron Pharmaceuticals | 8.46% |
Gilead Sciences, Inc. | 7.55% |
Moderna, Inc. | 3.96% |
AstraZeneca PLC ADR | 3.81% |
Biogen, Inc. | 3.68% |
Illumina | 2.34% |
Alnylam Pharmaceuticals | 2.23% |
BioMarin Pharmaceutical | 1.71% |
United States | 83.79% |
Ireland | 1.42% |
Germany | 1.05% |
Other | 13.74% |
Health Care | 88.93% |
Other | 11.07% |
Broker | Rating | Savings plan offer | Brokerage fee | More information |
---|---|---|---|---|
free of charge | free of charge | More info | ||
free of charge | free of charge | More info | ||
free of charge | free of charge | More info | ||
free of charge | free of charge | More info | ||
free of charge | free of charge | More info |
YTD | +3.85% |
1 month | -3.10% |
3 months | +2.95% |
6 months | +8.81% |
1 year | +9.81% |
3 years | +4.22% |
5 years | +37.27% |
Since inception (MAX) | +40.52% |
2023 | +0.53% |
2022 | -5.02% |
2021 | +7.94% |
2020 | +15.18% |
Volatility 1 year | 17.32% |
Volatility 3 years | 23.13% |
Volatility 5 years | 25.53% |
Return per risk 1 year | 0.57 |
Return per risk 3 years | 0.06 |
Return per risk 5 years | 0.26 |
Maximum drawdown 1 year | -12.19% |
Maximum drawdown 3 years | -30.93% |
Maximum drawdown 5 years | -30.93% |
Maximum drawdown since inception | -30.93% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | 2B70 | - - | - - | - |
Stuttgart Stock Exchange | EUR | 2B70 | - - | - - | - |
Bolsa Mexicana de Valores | MXN | - | BTEC1N MM | BTEC1N.MX | |
London Stock Exchange | USD | BTEC | BTEC LN INAVBTEU | BTEC.L 0WXSINAV.DE | |
London Stock Exchange | GBP | BTEK | BTEK LN INAVBTEU | BTEK.L 0WXSINAV.DE | |
SIX Swiss Exchange | USD | BTEC | BTEC SE INAVBTEU | BTEC.S 0WXSINAV.DE | |
XETRA | EUR | 2B70 | 2B70 GY INAVBTEE | BTEC.DE 0WXNINAV.DE |
Fund name | Fund Size in m € (AuM) | TER in % p.a. | Distribution policy | Replication method |
---|---|---|---|---|
Invesco Nasdaq Biotech UCITS ETF | 590 | 0.40% p.a. | Accumulating | Swap-based |
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 41 | 0.35% p.a. | Distributing | Sampling |